涎腺导管癌:组织学、细胞学、分子生物学与治疗进展
涎腺导管癌(SDC)是一种侵袭性原发涎腺癌,常见于老年男性腮腺,易转移复发。本文综述其组织学、细胞学、分子生物学及治疗进展,指出AR和HER2免疫组化有助诊断,NCCN指南推荐治疗前评估AR和HER2状态,分子分析发现TP53、HRAS、PIK3CA、PTEN和BRAF等基因改变。
要点
- SDC诊断依赖AR免疫组化表达及特征性组织形态。
- NCCN指南推荐治疗前评估AR和HER2状态。
- 细胞块辅助检查有助FNA样本的SDC特异诊断。
核心结论
- SDC是侵袭性原发涎腺癌,诊断依赖AR免疫组化及组织形态,治疗前应评估AR和HER2状态。
研究设计与样本
- 综述,总结SDC在组织学、细胞学、分子生物学和治疗方面的最新研究进展。
主要发现
- SDC最常见于老年男性腮腺,镜下类似高级别乳腺导管癌。
- FNA通常显示高级别癌的细胞学特征,细胞块辅助检查有助特异诊断。
- 手术标本中核异型性、核分裂计数、血管侵犯和浸润前沿形态是重要预后因素。
- 靶向AR和HER2的临床研究显示有前景的结果。
- 分子分析发现TP53、HRAS、PIK3CA、PTEN和BRAF等多基因异质性改变。
关键数值与推荐
- NCCN最新版指南推荐治疗前评估AR和HER2状态。
临床怎么用
- 对SDC疑似病例行AR免疫组化辅助诊断,治疗前检测AR和HER2状态以指导靶向治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Salivary duct carcinoma (SDC) is an aggressive subtype of primary salivary gland carcinoma, often with an advanced stage at presentation and high rates of metastasis and recurrence. It most commonly arises in the parotid gland of older men and microscopically resembles high-grade breast ductal carcinoma. While 50 years have lapsed since the first report of this entity, recent intensive studies have shed light on its biologic, genetic, and clinical characteristics. The diagnosis of SDC is aided by the immunohistochemical expression of androgen receptor (AR) coupled with its characteristic histomorphology. Fine-needle aspiration typically reveals cytologic features of high-grade carcinoma, and ancillary studies using cell block material can facilitate the specific diagnosis of SDC. In surgical specimens, certain histologic features are important prognostic factors, including nuclear pleomorphism, mitotic counts, vascular invasion, and the morphology at the invasion front. Several clinical studies have shown promising results using targeted therapy for AR and human epidermal growth factor receptor 2 (HER2), and the latest version of the National Comprehensive Cancer Network guidelines recommends the evaluation of AR and HER2 status before treatment. Recent molecular analyses have revealed multiple heterogeneous alterations in well-known oncogenes and tumor suppressor genes, including TP53, HRAS, PIK3CA, PTEN, and BRAF. Clinical trials of drugs targeting these genes may broaden the treatment options for SDC in the near future.
引用
- Nakaguro M, Tada Y, Faquin WC, et al. Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment. Cancer Cytopathol. 2020. PMID: 32421944. doi:10.1002/cncy.22288
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。